Straight Path Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Straight Path Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$1.56M	–	136
2025 Q4	$1.56M	Hold	50,000	–	–	0.42%	27
2025 Q3	$1.01M	Hold	50,000	–	–	0.27%	46
2025 Q2	$838K	Hold	50,000	–	–	0.28%	34
2025 Q1	$769K	Sell	50,000 -16,000	-24%	-$286K	0.31%	33
2024 Q4	$1.45M	Hold	66,000	–	–	0.58%	24
2024 Q3	$1.19M	Hold	66,000	–	–	0.51%	24
2024 Q2	$1.07M	Hold	66,000	–	–	0.55%	24
2024 Q1	$931K	Hold	66,000	–	–	0.52%	27
2023 Q4	$689K	Hold	66,000	–	–	0.4%	31
2023 Q3	$673K	Hold	66,000	–	–	0.46%	30
2023 Q2	$497K	Sell	66,000 -25,000	-27%	-$203K	0.34%	39
2023 Q1	$805K	Hold	91,000	–	–	0.64%	23
2022 Q4	$830K	Buy	91,000 +19,600	+27%	+$171K	0.8%	22
2022 Q3	$576K	Buy	71,400 +5,400	+8%	+$47.8K	0.52%	33
2022 Q2	$496K	Hold	66,000	–	–	0.49%	34
2022 Q1	$620K	Buy	66,000 +10,000	+18%	+$83.5K	0.53%	30
2021 Q4	$449K	Buy	+56,000	New	+$505K	0.39%	38

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Straight Path Wealth Management's TEVA Position: Q1 2026 in Review

Straight Path Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 50,000 shares — an estimated $1.56M sold.

Straight Path Wealth Management first reported a position in TEVA in Q4 2021 and held it in 17 quarters. The position peaked at $1.56M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Straight Path Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Straight Path Wealth Management sold 50,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
Straight Path Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 17 quarters.
Straight Path Wealth Management's Teva Pharmaceuticals position peaked at $1.56M in Q4 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Straight Path Wealth Management's 13F filing for Q1 2026, filed 23 Apr 2026.